Literature DB >> 15109671

Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4.

Vincent P Rocco1, Patrick G Spinazze, Todd J Kohn, Nicholas A Honigschmidt, David L Nelson, D Bradley Wainscott, Laura J Ahmad, Janice Shaw, Penny G Threlkeld, David T Wong, Kumiko Takeuchi.   

Abstract

A series of 1-(1H-indol-4-yloxy)-3-(4-arylpiperidinyl)propan-2-ols possessing potent dual 5-HT(1A) receptor antagonism and serotonin reuptake inhibition was discovered. The fused aryl ring moiety contributed to the robust dual activities irrespective of the regiochemistry associated with its connectivity to the piperidine central ring.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15109671     DOI: 10.1016/j.bmcl.2004.02.088

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant.

Authors:  C E Beyer; Q Lin; B Platt; J Malberg; G Hornby; K M Sullivan; D L Smith; T Lock; P J Mitchell; N T Hatzenbuhler; D A Evrard; B L Harrison; R Magolda; M N Pangalos; L E Schechter; S Rosenzweig-Lipson; T H Andree
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

2.  NO-SSRIs: Nitric Oxide Chimera Drugs Incorporating a Selective Serotonin Reuptake Inhibitor.

Authors:  Samer Abdul-Hay; Isaac T Schiefer; R Esala P Chandrasena; Min Li; Ramy Abdelhamid; Yue-Ting Wang; Ehsan Tavassoli; Bradley Michalsen; Rezene T Asghodom; Jia Luo; Gregory R J Thatcher
Journal:  ACS Med Chem Lett       Date:  2011-09-08       Impact factor: 4.345

3.  Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review.

Authors:  Nadeem Siddiqui; Sandhya Bawa; Ruhi Ali; Obaid Afzal; M Jawaid Akhtar; Bishmillah Azad; Rajiv Kumar
Journal:  J Pharm Bioallied Sci       Date:  2011-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.